Decreased background parenchymal enhancement of the contralateral breast after two cycles of neoadjuvant chemotherapy is associated with tumor response in HER2-positive breast cancer.

about

Decreased background parenchymal enhancement of the contralateral breast after two cycles of neoadjuvant chemotherapy is associated with tumor response in HER2-positive breast cancer.

Item

http://www.wikidata.org/entity/Q47727855

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Decreased background parenchym ...... n HER2-positive breast cancer.

@en

Decreased background parenchym ...... n HER2-positive breast cancer.

@nl

type

Item

label

Decreased background parenchym ...... n HER2-positive breast cancer.

@en

Decreased background parenchym ...... n HER2-positive breast cancer.

@nl

prefLabel

Decreased background parenchym ...... n HER2-positive breast cancer.

@en

Decreased background parenchym ...... n HER2-positive breast cancer.

@nl

P1476

Decreased background parenchym ...... n HER2-positive breast cancer.

@en

P2093

Chao You

http://www.w3.org/2001/XMLSchema#string

Guangyu Liu

http://www.w3.org/2001/XMLSchema#string

Jianwei Li

http://www.w3.org/2001/XMLSchema#string

Weijun Peng

http://www.w3.org/2001/XMLSchema#string

Wen Peng

http://www.w3.org/2001/XMLSchema#string

Xuxia Shen

http://www.w3.org/2001/XMLSchema#string

Yajia Gu

http://www.w3.org/2001/XMLSchema#string

P2860

Background Parenchymal Enhancement of the Contralateral Normal Breast: Association with Tumor Response in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.

Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?

18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.

Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.

Automated extraction of BI-RADS final assessment categories from radiology reports with natural language processing.

Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI.

Reducing delay in the diagnosis of pregnancy-associated breast cancer: how imaging can help us.

Impact of menopausal status on background parenchymal enhancement and fibroglandular tissue on breast MRI.

P304

284185117738560

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0284185117738560

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29065702

http://www.w3.org/2001/XMLSchema#string